# A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07637578** · PHASE2 · RECRUITING · sponsor: **SCRI Development Innovations, LLC** · enrollment: 46 (estimated)

## Conditions studied

- Multiple Myeloma (MM)
- Multiple Myeloma Refractory
- Multiple Myeloma in Relapse
- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07637578
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-10
- **Final completion:** 2030-02
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637578, "A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*